COGT
Cogent Biosciences, Inc. [COGT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
COGT Stock Summary
In the News
COGT Financial details
Company Rating
Neutral
Market Cap
676.47M
Income
-187.76M
Revenue
0
Book val./share
2.97
Cash/share
3.06
Dividend
-
Dividend %
-
Employees
164
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-2.68
Forward P/E
-
PEG
-7.57
P/S
-
P/B
1.49
P/C
2.17
P/FCF
-4.29
Quick Ratio
8.04
Current Ratio
9.01
Debt / Equity
0.07
LT Debt / Equity
0.07
-
-
EPS (TTM)
-2.34
EPS next Y
-
EPS next Q
-
EPS this Y
7.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-9.43%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-1.56%
-
-
-
-
SMA20
-
SMA50
40%
SMA100
-
Inst Own
82.23%
Inst Trans
0.66%
ROA
-48%
ROE
-60%
ROC
-0.6%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.67-13.5
52W High
-48.96%
52W Low
+121.17%
RSI
50
Rel Volume
0.22
Avg Volume
2.19M
Volume
487.3K
Perf Week
-0.23%
Perf Month
-1.26%
Perf Quarter
-24.69%
Perf Half Y
-29.71%
-
-
-
-
Beta
-0.081
-
-
Volatility
0.05%, 0.27%
Prev Close
1.61%
Price
6.635
Change
1.76%
COGT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.95 | 0.71 | 0 | 0 | 0 | |
| Net income per share | -3.97 | -6 | -1.85 | -2.26 | -2.42 | |
| Operating cash flow per share | -5.45 | -3.24 | -1.52 | -2.02 | -1.93 | |
| Free cash flow per share | -5.45 | -3.24 | -1.56 | -2.14 | -1.96 | |
| Cash per share | 4.91 | 21.86 | 5.67 | 4.41 | 3.34 | |
| Book value per share | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | |
| Tangible book value per share | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | |
| Share holders equity per share | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | |
| Interest debt per share | 0.79 | 0.47 | 0.08 | 0.4 | 0.24 | |
| Market cap | 21.95M | 124.44M | 332.31M | 679.03M | 468.39M | |
| Enterprise value | -9.45M | -112.54M | 115.78M | 558.79M | 434.01M | |
| P/E ratio | -0.72 | -1.87 | -4.63 | -5.12 | -2.43 | |
| Price to sales ratio | 0.98 | 15.81 | 0 | 0 | 0 | |
| POCF ratio | -0.53 | -3.47 | -5.66 | -5.72 | -3.05 | |
| PFCF ratio | -0.53 | -3.47 | -5.49 | -5.41 | -2.99 | |
| P/B Ratio | 0.69 | 0.53 | 1.55 | 2.66 | 1.82 | |
| PTB ratio | 0.69 | 0.53 | 1.55 | 2.66 | 1.82 | |
| EV to sales | -0.42 | -14.3 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.29 | 1.25 | -1.54 | -3.78 | -2.12 | |
| EV to operating cash flow | 0.23 | 3.14 | -1.97 | -4.71 | -2.83 | |
| EV to free cash flow | 0.23 | 3.14 | -1.91 | -4.45 | -2.77 | |
| Earnings yield | -1.38 | -0.53 | -0.22 | -0.2 | -0.41 | |
| Free cash flow yield | -1.89 | -0.29 | -0.18 | -0.18 | -0.33 | |
| Debt to equity | 0.19 | 0.02 | 0.01 | 0.08 | 0.07 | |
| Debt to assets | 0.12 | 0.02 | 0.01 | 0.07 | 0.06 | |
| Net debt to EBITDA | 0.98 | 2.64 | 2.87 | 0.81 | 0.17 | |
| Current ratio | 3.06 | 18.7 | 13.04 | 9.87 | 7.09 | |
| Interest coverage | 0 | 0 | 0 | -37.06 | 0 | |
| Income quality | 1.3 | 0.48 | 0.81 | 0.85 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.49 | 2.21 | 0 | 0 | 0 | |
| Research and developement to revenue | 1.94 | 9.23 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.03 | 0.06 | 0.02 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.03 | 0 | -11.69 | -1.17 | -0.78 | |
| Stock based compensation to revenue | 0.14 | 0.76 | 0 | 0 | 0 | |
| Graham number | 19.3 | 53.45 | 15.19 | 14.87 | 13.26 | |
| ROIC | -0.7 | -0.3 | -0.34 | -0.47 | -0.7 | |
| Return on tangible assets | -0.61 | -0.26 | -0.31 | -0.44 | -0.61 | |
| Graham Net | 2.79 | 20.39 | 5.21 | 3.65 | 2.64 | |
| Working capital | 27.34M | 231.82M | 205.56M | 238.12M | 232.6M | |
| Tangible asset value | 31.76M | 234.67M | 214.18M | 255.74M | 257.8M | |
| Net current asset value | 22.93M | 228.66M | 204.73M | 219.89M | 215.14M | |
| Invested capital | 0.19 | 0.02 | 0.01 | 0.08 | 0.07 | |
| Average receivables | 1.83M | 1000K | 0 | 0 | 0 | |
| Average payables | 2.35M | 1.96M | 2.11M | 4.66M | 8.25M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 32.45 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 26.58K | 10.38K | 8.65K | 362.76 | 1.08K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 11.25 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.04 | 0.04 | 1.01 | 0.34 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.95 | -0.28 | -0.34 | -0.52 | -0.75 | |
| Capex per share | 0 | 0 | -0.04 | -0.12 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.5 | -0.48 | -0.59 | -0.64 | -0.63 | |
| Operating cash flow per share | -0.42 | -0.56 | -0.43 | -0.44 | -0.51 | |
| Free cash flow per share | -0.45 | -0.57 | -0.45 | -0.44 | -0.51 | |
| Cash per share | 3.68 | 3.11 | 4.41 | 3.24 | 3.06 | |
| Book value per share | 3.63 | 3.16 | 4.66 | 3.52 | 2.97 | |
| Tangible book value per share | 3.63 | 3.16 | 4.66 | 3.52 | 2.97 | |
| Share holders equity per share | 3.63 | 3.16 | 4.66 | 3.52 | 2.97 | |
| Interest debt per share | 0.31 | 0.21 | 0.26 | 0.22 | 0.22 | |
| Market cap | 814.86M | 763.23M | 885.08M | 840.12M | 509.97M | |
| Enterprise value | 694.62M | 621.99M | 690.12M | 772.48M | 475.6M | |
| P/E ratio | -5.74 | -5.62 | -5.02 | -3.79 | -2.35 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -27.71 | -19.31 | -27.6 | -22.13 | -11.57 | |
| PFCF ratio | -25.97 | -18.79 | -26.56 | -22.05 | -11.49 | |
| P/B Ratio | 3.19 | 3.41 | 2.54 | 2.77 | 1.98 | |
| PTB ratio | 3.19 | 3.41 | 2.54 | 2.77 | 1.98 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -15.88 | -14.63 | -14.66 | -12.97 | -8.28 | |
| EV to operating cash flow | -23.62 | -15.74 | -21.52 | -20.34 | -10.79 | |
| EV to free cash flow | -22.14 | -15.31 | -20.71 | -20.28 | -10.72 | |
| Earnings yield | -0.04 | -0.04 | -0.05 | -0.07 | -0.11 | |
| Free cash flow yield | -0.04 | -0.05 | -0.04 | -0.05 | -0.09 | |
| Debt to equity | 0.08 | 0.09 | 0.06 | 0.06 | 0.07 | |
| Debt to assets | 0.07 | 0.07 | 0.05 | 0.05 | 0.06 | |
| Net debt to EBITDA | 2.75 | 3.32 | 4.14 | 1.14 | 0.6 | |
| Current ratio | 9.87 | 10.71 | 12.99 | 9.01 | 7.09 | |
| Interest coverage | -20.73 | 9.3 | 0 | 0 | 0 | |
| Income quality | 0.74 | 1.02 | 0.73 | 0.69 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.07 | 0.03 | 0.04 | 0 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.1 | -1.53 | -1.03 | -0.14 | -0.4 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.41 | 5.84 | 7.86 | 7.13 | 6.47 | |
| ROIC | -0.13 | -0.14 | -0.11 | -0.17 | -0.18 | |
| Return on tangible assets | -0.12 | -0.13 | -0.11 | -0.16 | -0.17 | |
| Graham Net | 3.04 | 2.55 | 3.82 | 2.63 | 2.42 | |
| Working capital | 238.12M | 205.15M | 308.76M | 278.12M | 232.6M | |
| Tangible asset value | 255.74M | 223.56M | 348.43M | 302.9M | 257.8M | |
| Net current asset value | 219.89M | 186.64M | 290.58M | 260.29M | 215.14M | |
| Invested capital | 0.08 | 0.09 | 0.06 | 0.06 | 0.07 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.97M | 5.01M | 5.67M | 8.51M | 10.26M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 561.13 | 519.34 | 530.01 | 1.04K | 1.21K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.16 | 0.17 | 0.17 | 0.09 | 0.07 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.14 | -0.15 | -0.13 | -0.18 | -0.21 | |
| Capex per share | -0.03 | -0.02 | -0.02 | 0 | 0 |
COGT Frequently Asked Questions
What is Cogent Biosciences, Inc. stock symbol ?
Cogent Biosciences, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol COGT
What is Cogent Biosciences, Inc. stock quote today ?
Cogent Biosciences, Inc. stock price is $6.635 today.
Is Cogent Biosciences, Inc. stock public?
Yes, Cogent Biosciences, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.19M
- Market Capitalization 676.47M
- Employee 164
- CEO Mr. Andrew R. Robbins M.B.A.
- Headquarters Cambridge,MA,US
- IPO Date 2018-03-29
-
Website
https://www.cogentbio.com 
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
